Karolinska Development’s portfolio company SVF Vaccines presents positive data from a preclinical study of SVF-001 in chronic hepatitis B and D

Core Insights - Karolinska Development AB's portfolio company SVF Vaccines has reported positive preclinical study results for its immunotherapy SVF-001, which targets chronic hepatitis B and D [1][2][4] Company Overview - SVF Vaccines specializes in developing DNA vaccines and immunotherapies based on proprietary technology from Karolinska Institutet [2] - Karolinska Development holds a 33% ownership stake in SVF Vaccines [5] Study Results - The preclinical study showed an antiviral effect in a humanized-liver mouse model of chronic HBV/HDV coinfection, with significant reductions in hepatitis B virus DNA and hepatitis D virus RNA levels in blood following SVF-001 administration [3] - The results presented at scientific meetings indicate the therapeutic potential of SVF-001 for patients coinfected with chronic hepatitis B and D [4] Future Prospects - SVF Vaccines is focused on developing next-generation therapeutic and prophylactic vaccines that could prevent disease and cure infected patients [4] - The company also has early-stage discovery programs targeting other serious infectious diseases [5]